Abstract
The following results were obtained by our fundamental and clinical studies of a new antifungal agent, 3-(p-methylbenzylideneamino)-4-phenylthiazoline-2-thione (TBK).
1) The antifungal effect in vitro was found at the concentration of 3.12γ/cc against trichophyton mentagrophytes, 1.5γ/cc against trichophyton rubrum, and over 100γ/cc against candida albicans.
2) The healing rate of experimental trichophytia was 100 percent.
3) Clinically TBK-I solution (1%) and TBK-II solution (2%) were applied to 7 cases with tinea cruris and 17 cases with tinea pedis.
TBK-I solution was very effective in 11 cases, effective in 7 cases, slightly effective in 2 cases, and ineffective in 4 cases.
TBK-II solution was very effective in 12 cases, effective in 5 cases, slightly effective in 2 cases, and ineffective in 5 cases.
4) Side effects were observed in 2 cases.
